Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 118

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Diagnosis and Treatment of Acromegaly: An Update

Ershadinia, Nazanin, Tritos, Nicholas A.·2022·Mayo Clinic Proceedings
DOI 10.1016/j.mayocp.2021.11.007
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.mayocp.2021.11.007

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 109

  1. Melmed, 2020, Pituitary-tumor endocrinopathies, N Engl J Med, 382, 937, 10.1056/NEJMra1810772 · DOI · Paper page
  2. Fleseriu, 2021, A Pituitary Society update to acromegaly management guidelines, Pituitary, 24, 1, 10.1007/s11102-020-01091-7 · DOI · Paper page
  3. Katznelson, 2014, Acromegaly: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab, 99, 3933, 10.1210/jc.2014-2700 · DOI · Paper page
  4. Nass, 2010, Ghrelin and growth hormone: story in reverse, Proc Natl Acad Sci U S A, 107, 8501, 10.1073/pnas.1002941107 · DOI
  5. Melmed, 2019, Pathogenesis and diagnosis of growth hormone deficiency in adults, N Engl J Med, 380, 2551, 10.1056/NEJMra1817346 · DOI · Paper page
  6. Clemmons, 2011, Clinical laboratory indices in the treatment of acromegaly, Clin Chim Acta, 412, 403, 10.1016/j.cca.2010.11.008 · DOI
  7. Clemmons, 2011, Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays, Clin Chem, 57, 555, 10.1373/clinchem.2010.150631 · DOI · Paper page
  8. Brooks, 2014, Mechanism of activation of protein kinase JAK2 by the growth hormone receptor, Science, 344, 1249783, 10.1126/science.1249783 · DOI · Paper page
  9. Carter-Su, 2016, Growth hormone signaling pathways, Growth Horm IGF Res, 28, 11, 10.1016/j.ghir.2015.09.002 · DOI
  10. Hakuno, 2018, IGF1 receptor signaling pathways, J Mol Endocrinol, 61, T69, 10.1530/JME-17-0311 · DOI · Paper page
  11. Cuevas-Ramos, 2015, A structural and functional acromegaly classification, J Clin Endocrinol Metab, 100, 122, 10.1210/jc.2014-2468 · DOI
  12. Lopes, 2017, The 2017 World Health Organization classification of tumors of the pituitary gland: a summary, Acta Neuropathol, 134, 521, 10.1007/s00401-017-1769-8 · DOI · Paper page
  13. Hage, 2018, Genomic alterations and complex subclonal architecture in sporadic GH-secreting pituitary adenomas, J Clin Endocrinol Metab, 103, 1929, 10.1210/jc.2017-02287 · DOI
  14. Boguslawska, 2021, Genetics of acromegaly and gigantism, J Clin Med, 10, 1377
  15. Karges, 2004, Acromegaly induced by growth hormone replacement therapy, Horm Res, 61, 165
  16. Thorner, 1982, Somatotroph hyperplasia. Successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor, J Clin Invest, 70, 965, 10.1172/JCI110708 · DOI · Paper page
  17. Beuschlein, 2000, Acromegaly caused by secretion of growth hormone by a non-Hodgkin's lymphoma, N Engl J Med, 342, 1871, 10.1056/NEJM200006223422504 · doi:10.1056/nejm200006223422504
  18. Melmed, 1985, Acromegaly due to secretion of growth hormone by an ectopic pancreatic islet-cell tumor, N Engl J Med, 312, 9, 10.1056/NEJM198501033120103 · doi:10.1056/nejm198501033120103
  19. Langlois, 2018, Silent somatotroph pituitary adenomas: an update, Pituitary, 21, 194, 10.1007/s11102-017-0858-y · DOI
  20. Giustina, 2020, A consensus on the diagnosis and treatment of acromegaly comorbidities: an update, J Clin Endocrinol Metab, 105, dgz096, 10.1210/clinem/dgz096 · DOI · Paper page
  21. Caron, 2019, Signs and symptoms of acromegaly at diagnosis: the physician's and the patient's perspectives in the ACRO-POLIS study [erratum appears in Endocrine. 2019;63(1):130], Endocrine, 63, 120, 10.1007/s12020-018-1764-4 · DOI
  22. Reid, 2010, Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed, Clin Endocrinol (Oxf), 72, 203, 10.1111/j.1365-2265.2009.03626.x · doi:10.1111/j.1365-2265.2009.03626.x
  23. Esposito, 2020, Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality, Eur J Endocrinol, 182, 523, 10.1530/EJE-20-0019 · DOI · Paper page
  24. Schneider, 2011, A novel approach to the detection of acromegaly: accuracy of diagnosis by automatic face classification, J Clin Endocrinol Metab, 96, 2074, 10.1210/jc.2011-0237 · DOI
  25. Kong, 2018, Automatic detection of acromegaly from facial photographs using machine learning methods, EBioMedicine, 27, 94, 10.1016/j.ebiom.2017.12.015 · DOI
  26. Bonert, 2018, Discordance between mass spectrometry and immunometric IGF-1 assay in pituitary disease: a prospective study, Pituitary, 21, 65, 10.1007/s11102-017-0849-z · DOI
  27. Bystrom, 2012, Clinical utility of insulin-like growth factor 1 and 2; determination by high resolution mass spectrometry, PLoS One, 7, 10.1371/journal.pone.0043457 · DOI
  28. Johannsson, 2018, Growth Hormone Research Society perspective on biomarkers of GH action in children and adults, Endocr Connect, 7, R126, 10.1530/EC-18-0047 · DOI
  29. Schilbach, 2017, Biochemical investigations in diagnosis and follow up of acromegaly, Pituitary, 20, 33, 10.1007/s11102-017-0792-z · DOI
  30. Leung, 2003, Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2, Proc Natl Acad Sci U S A, 100, 1016, 10.1073/pnas.0337600100 · DOI · Paper page
  31. Schilbach, 2019, Determinants of the growth hormone nadir during oral glucose tolerance test in adults, Eur J Endocrinol, 181, 55, 10.1530/EJE-19-0139 · DOI
  32. Ribeiro-Oliveira, 2011, Limited utility of oral glucose tolerance test in biochemically active acromegaly, Eur J Endocrinol, 164, 17, 10.1530/EJE-10-0744 · DOI
  33. Lonser, 2010, Acromegaly without imaging evidence of pituitary adenoma, J Clin Endocrinol Metab, 95, 4192, 10.1210/jc.2010-0570 · doi:10.1210/jc.2010-0570
  34. Ritvonen, 2016, Mortality in acromegaly: a 20-year follow-up study, Endocr Relat Cancer, 23, 469, 10.1530/ERC-16-0106 · DOI · Paper page
  35. Dal, 2018, Cancer incidence in patients with acromegaly: a cohort study and meta-analysis of the literature, J Clin Endocrinol Metab, 103, 2182, 10.1210/jc.2017-02457 · DOI
  36. Holdaway, 2008, A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly, Eur J Endocrinol, 159, 89, 10.1530/EJE-08-0267 · DOI · Paper page
  37. Giustina, 2020, Multidisciplinary management of acromegaly: a consensus, Rev Endocr Metab Disord, 21, 667, 10.1007/s11154-020-09588-z · DOI · Paper page
  38. Bollerslev, 2019, Management of endocrine disease: individualised management of acromegaly, Eur J Endocrinol, 181, R57, 10.1530/EJE-19-0124 · doi:10.1530/eje-19-0124
  39. Yao, 2021, Predictors of postoperative biochemical remission in acromegaly, J Neurooncol, 151, 313, 10.1007/s11060-020-03669-4 · doi:10.1007/s11060-020-03669-4
  40. Fougner, 2014, Preoperative octreotide treatment of acromegaly: long-term results of a randomised controlled trial, Eur J Endocrinol, 171, 229, 10.1530/EJE-14-0249 · doi:10.1530/eje-14-0249
  41. Shen, 2010, Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study, Endocr J, 57, 1035, 10.1507/endocrj.K10E-203 · doi:10.1507/endocrj.k10e-203
  42. Wildemberg, 2021, Machine learning–based prediction model for treatment of acromegaly with first-generation somatostatin receptor ligands, J Clin Endocrinol Metab, 106, 2047, 10.1210/clinem/dgab125 · DOI
  43. Chen, 2017, Microsurgical versus endoscopic transsphenoidal resection for acromegaly: a systematic review of outcomes and complications, Acta Neurochir (Wien), 159, 2193, 10.1007/s00701-017-3318-6 · doi:10.1007/s00701-017-3318-6
  44. Fathalla, 2015, Endoscopic versus microscopic approach for surgical treatment of acromegaly, Neurosurg Rev, 38, 541, 10.1007/s10143-015-0613-7 · doi:10.1007/s10143-015-0613-7
  45. Buchfelder, 2017, The surgical treatment of acromegaly, Pituitary, 20, 76, 10.1007/s11102-016-0765-7 · doi:10.1007/s11102-016-0765-7
  46. Swearingen, 1998, Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly, J Clin Endocrinol Metab, 83, 3419
  47. Babu, 2017, Long-term endocrine outcomes following endoscopic endonasal transsphenoidal surgery for acromegaly and associated prognostic factors, Neurosurgery, 81, 357, 10.1093/neuros/nyx020 · DOI
  48. Coopmans, 2021, Predictors for remission after transsphenoidal surgery in acromegaly: a Dutch multicenter study, J Clin Endocrinol Metab, 106, 1783, 10.1210/clinem/dgab069 · doi:10.1210/clinem/dgab069
  49. Anthony, 2015, Significant elevation of growth hormone level impacts surgical outcomes in acromegaly, Endocr Pract, 21, 1001, 10.4158/EP14587.OR · DOI
  50. Kim, 2012, Predicting long-term remission by measuring immediate postoperative growth hormone levels and oral glucose tolerance test in acromegaly, Neurosurgery, 70, 1106, 10.1227/NEU.0b013e31823f5c16 · DOI
  51. Agrawal, 2020, Prognostic factors of biochemical remission after transsphenoidal surgery for acromegaly: a structured review, Pituitary, 23, 582, 10.1007/s11102-020-01063-x · DOI
  52. Fahlbusch, 2017, Surgical debulking of pituitary adenomas improves responsiveness to octreotide lar in the treatment of acromegaly, Pituitary, 20, 668, 10.1007/s11102-017-0832-8 · DOI
  53. Zhang, 2018, The comprehensive impact on human body induced by resolution of growth hormone excess, Eur J Endocrinol, 178, 365, 10.1530/EJE-17-0872 · DOI
  54. Gunther, 2018, International Union of Basic and Clinical Pharmacology. CV. Somatostatin receptors: structure, function, ligands, and new nomenclature, Pharmacol Rev, 70, 763, 10.1124/pr.117.015388 · DOI · Paper page
  55. Carmichael, 2014, Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis, J Clin Endocrinol Metab, 99, 1825, 10.1210/jc.2013-3757 · DOI · Paper page
  56. Caron, 2014, Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial, J Clin Endocrinol Metab, 99, 1282, 10.1210/jc.2013-3318 · DOI · Paper page
  57. Samson, 2020, Maintenance of acromegaly control in patients switching from injectable somatostatin receptor ligands to oral octreotide, J Clin Endocrinol Metab, 105, e3785, 10.1210/clinem/dgaa526 · doi:10.1210/clinem/dgaa526
  58. Giustina, 2012, Meta-analysis on the effects of octreotide on tumor mass in acromegaly, PLoS One, 7, 10.1371/journal.pone.0036411 · DOI · Paper page
  59. Petersenn, 2020, Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study, Pituitary, 23, 171, 10.1007/s11102-019-01020-3 · DOI
  60. Brzana, 2013, Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience, Pituitary, 16, 490, 10.1007/s11102-012-0445-1 · doi:10.1007/s11102-012-0445-1
  61. Galm, 2020, MRI texture analysis in acromegaly and its role in predicting response to somatostatin receptor ligands, Pituitary, 23, 212, 10.1007/s11102-019-01023-0 · doi:10.1007/s11102-019-01023-0
  62. Newman, 1995, Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients—a clinical research center study [erratum appears in J Clin Endocrinol Metab. 1995;80(11):3238], J Clin Endocrinol Metab, 80, 2768
  63. Daly, 2010, Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study, J Clin Endocrinol Metab, 95, E373, 10.1210/jc.2009-2556 · DOI · Paper page
  64. Bogner, 2020, miR-34a is upregulated in AIP-mutated somatotropinomas and promotes octreotide resistance, Int J Cancer, 147, 3523, 10.1002/ijc.33268 · doi:10.1002/ijc.33268
  65. Beckers, 2015, X-linked acrogigantism syndrome: clinical profile and therapeutic responses, Endocr Relat Cancer, 22, 353, 10.1530/ERC-15-0038 · DOI · Paper page
  66. Salenave, 2014, Acromegaly and McCune-Albright syndrome, J Clin Endocrinol Metab, 99, 1955, 10.1210/jc.2013-3826 · doi:10.1210/jc.2013-3826
  67. Efstathiadou, 2015, Impact of gsp mutations in somatotroph pituitary adenomas on growth hormone response to somatostatin analogs: a meta-analysis, Pituitary, 18, 861, 10.1007/s11102-015-0662-5 · doi:10.1007/s11102-015-0662-5
  68. Larkin, 2013, Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas, Eur J Endocrinol, 168, 491, 10.1530/EJE-12-0864 · doi:10.1530/eje-12-0864
  69. Asa, 2021, An update on pituitary neuroendocrine tumors leading to acromegaly and gigantism, J Clin Med, 10, 2254
  70. Bhayana, 2005, The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly, J Clin Endocrinol Metab, 90, 6290, 10.1210/jc.2005-0998 · doi:10.1210/jc.2005-0998
  71. Kasuki, 2013, Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern, Eur J Endocrinol, 169, 217, 10.1530/EJE-13-0349 · doi:10.1530/eje-13-0349
  72. Taboada, 2008, Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR, Eur J Endocrinol, 158, 295, 10.1530/EJE-07-0562 · DOI · Paper page
  73. Kasuki, 2012, AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression, Endocr Relat Cancer, 19, L25, 10.1530/ERC-12-0020 · doi:10.1530/erc-12-0020
  74. Gatto, 2016, Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly, Eur J Endocrinol, 174, 651, 10.1530/EJE-15-0391 · DOI
  75. Venegas-Moreno, 2019, E-cadherin expression is associated with somatostatin analogue response in acromegaly, J Cell Mol Med, 23, 3088, 10.1111/jcmm.13851 · doi:10.1111/jcmm.13851
  76. Theodoropoulou, 2010, ZAC1 target genes and pituitary tumorigenesis, Mol Cell Endocrinol, 326, 60, 10.1016/j.mce.2010.01.033 · DOI
  77. Theodoropoulou, 2009, Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly, Int J Cancer, 125, 2122, 10.1002/ijc.24602 · doi:10.1002/ijc.24602
  78. Theodoropoulou, 2006, Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression, Cancer Res, 66, 1576, 10.1158/0008-5472.CAN-05-1189 · DOI · Paper page
  79. Fougner, 2008, Low levels of raf kinase inhibitory protein in growth hormone–secreting pituitary adenomas correlate with poor response to octreotide treatment, J Clin Endocrinol Metab, 93, 1211, 10.1210/jc.2007-2272 · doi:10.1210/jc.2007-2272
  80. Heck, 2016, Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly, Endocrine, 52, 333, 10.1007/s12020-015-0766-8 · doi:10.1007/s12020-015-0766-8
  81. Heck, 2012, Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly, Clin Endocrinol (Oxf), 77, 72, 10.1111/j.1365-2265.2011.04286.x · doi:10.1111/j.1365-2265.2011.04286.x
  82. Puig-Domingo, 2010, Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure, J Clin Endocrinol Metab, 95, 4973, 10.1210/jc.2010-0573 · doi:10.1210/jc.2010-0573
  83. Tourassi, 1999, Journey toward computer-aided diagnosis: role of image texture analysis, Radiology, 213, 317, 10.1148/radiology.213.2.r99nv49317 · DOI · Paper page
  84. Colao, 2014, Pasireotide versus octreotide in acromegaly: a head-to-head superiority study, J Clin Endocrinol Metab, 99, 791, 10.1210/jc.2013-2480 · DOI · Paper page
  85. Gadelha, 2014, Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial, Lancet Diabetes Endocrinol, 2, 875, 10.1016/S2213-8587(14)70169-X · DOI · Paper page
  86. Iacovazzo, 2016, Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study, Eur J Endocrinol, 174, 241, 10.1530/EJE-15-0832 · doi:10.1530/eje-15-0832
  87. Muhammad, 2019, Pasireotide responsiveness in acromegaly is mainly driven by somatostatin receptor subtype 2 expression, J Clin Endocrinol Metab, 104, 915, 10.1210/jc.2018-01524 · doi:10.1210/jc.2018-01524
  88. Coopmans, 2020, T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly, Eur J Endocrinol, 182, 595, 10.1530/EJE-19-0840 · DOI
  89. Sandret, 2011, Place of cabergoline in acromegaly: a meta-analysis, J Clin Endocrinol Metab, 96, 1327, 10.1210/jc.2010-2443 · DOI · Paper page
  90. Zanettini, 2007, Valvular heart disease and the use of dopamine agonists for Parkinson's disease, N Engl J Med, 356, 39, 10.1056/NEJMoa054830 · DOI · Paper page
  91. Stiles, 2021, Incidence of cabergoline-associated valvulopathy in primary care patients with prolactinoma using hard cardiac endpoints, J Clin Endocrinol Metab, 106, e711, 10.1210/clinem/dgaa882 · DOI
  92. De Sousa, 2020, Impulse control disorders in dopamine agonist-treated hyperprolactinemia: prevalence and risk factors, J Clin Endocrinol Metab, 105, dgz076, 10.1210/clinem/dgz076 · DOI
  93. Kopchick, 2003, Discovery and mechanism of action of pegvisomant, Eur J Endocrinol, 148, S21, 10.1530/eje.0.148s021 · doi:10.1530/eje.0.148s021
  94. Trainer, 2000, Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant, N Engl J Med, 342, 1171, 10.1056/NEJM200004203421604 · DOI · Paper page
  95. van der Lely, 2001, Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist, Lancet, 358, 1754, 10.1016/S0140-6736(01)06844-1 · DOI · Paper page
  96. Fleseriu, 2021, More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY, Eur J Endocrinol, 185, 525, 10.1530/EJE-21-0239 · DOI
  97. Barkan, 2005, Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant, J Clin Endocrinol Metab, 90, 5684, 10.1210/jc.2005-0331 · DOI · Paper page
  98. Sievers, 2015, Prediction of therapy response in acromegalic patients under pegvisomant therapy within the German ACROSTUDY cohort, Pituitary, 18, 916, 10.1007/s11102-015-0673-2 · doi:10.1007/s11102-015-0673-2
  99. Droste, 2014, Therapy of acromegalic patients exacerbated by concomitant type 2 diabetes requires higher pegvisomant doses to normalise IGF1 levels [erratum appears in Eur J Endocrinol. 2014;171(6):X5], Eur J Endocrinol, 171, 59, 10.1530/EJE-13-0438 · DOI
  100. Neggers, 2007, Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly, J Clin Endocrinol Metab, 92, 4598, 10.1210/jc.2007-1234 · doi:10.1210/jc.2007-1234
  101. Qiao, 2020, Comparative efficacy of medical treatment for acromegaly: a systematic review and network meta-analysis of integrated randomized trials and observational studies, Endocr Pract, 26, 454, 10.4158/EP-2019-0528 · DOI
  102. Franck, 2017, A multivariable prediction model for pegvisomant dosing: monotherapy and in combination with long-acting somatostatin analogues, Eur J Endocrinol, 176, 421, 10.1530/EJE-16-0956 · doi:10.1530/eje-16-0956
  103. Buchfelder, 2018, Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY, Eur J Endocrinol, 179, 419, 10.1530/EJE-18-0616 · doi:10.1530/eje-18-0616
  104. Melmed, 2016, New therapeutic agents for acromegaly, Nat Rev Endocrinol, 12, 90, 10.1038/nrendo.2015.196 · DOI
  105. Antunes, 2021, New and emerging pharmacological treatment options for acromegaly, Expert Opin Pharmacother, 22, 1615, 10.1080/14656566.2021.1908998 · doi:10.1080/14656566.2021.1908998
  106. Lee, 2014, Stereotactic radiosurgery for acromegaly, J Clin Endocrinol Metab, 99, 1273, 10.1210/jc.2013-3743 · DOI
  107. Gheorghiu, 2017, Updates in outcomes of stereotactic radiation therapy in acromegaly, Pituitary, 20, 154, 10.1007/s11102-016-0783-5 · DOI
  108. Knappe, 2020, Fractionated radiotherapy and radiosurgery in acromegaly: analysis of 352 patients from the German Acromegaly Registry, Eur J Endocrinol, 182, 275, 10.1530/EJE-19-0784 · DOI
  109. Shih, 2008, Radiation therapy in acromegaly, Rev Endocr Metab Disord, 9, 59, 10.1007/s11154-007-9065-x · DOI

Metadata

Authors
Ershadinia, N., & Tritos, N. A.
Venue
Mayo Clinic Proceedings
Publisher
Elsevier BV
Published
2022-02
Volume
97
Issue
2
Pages
333-346
ISSN
0025-6196
DOI
10.1016/j.mayocp.2021.11.007
Cited by
118
References
1
Language
en
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Diagnosis and Treatment of Acromegaly: An Update. https://app.cochat.ai/papers/10.1016/j.mayocp.2021.11.007
The paper
Ershadinia, N., & Tritos, N. A. (2022). Diagnosis and Treatment of Acromegaly: An Update. Mayo Clinic Proceedings. https://doi.org/10.1016/j.mayocp.2021.11.007

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.